FDA Approved: WYNZORA — Original Application (MC2 Therapeutics Ltd)

View source ↗

Summary

FDA approved Wynzora, a fixed-dose combination of calcipotriene and betamethasone dipropionate, under an original NDA by MC2 Therapeutics Ltd for plaque psorias…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Plaque Psoriasis

Drugs mentioned

• WYNZORA (calcipotriene and betamethasone dipropionate)

Snippet

ORIG AP for WYNZORA (CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE)